Amid FDA tumult, agency misses decision deadline on Novavax's COVID shot
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 shot. The missed deadline comes shortly after the departure of the FDA's chief vaccine official Peter Marks, M.D., Ph.D., and as wider concerns mount about an anti-vaccine agenda under HHS secretary Robert F. Kennedy Jr.
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 shot. The missed deadline comes shortly after the departure of the FDA's chief vaccine official Peter Marks, M.D., Ph.D., and as wider concerns mount about an anti-vaccine agenda under HHS secretary Robert F. Kennedy Jr.
